ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3014

Does the Order or Amount of Risk-Benefit Information Presented Influence patients’ Perceived Value of a Proposed New Medication?

Liana Fraenkel1, Richard Street2, Harjinder Chowdhary3, Sarah Swift3 and Ellen Peters4, 1Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 2Texas A&M University, College Station, TX, 3Yale University, New Haven, CT, 4Ohio State University, Columbus, OH

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Racial Disparities and Risk Communication

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innovations in Rheumatologic Care

Session Type: Abstract Submissions (ARHP)

Background/Purpose: The order and amount of information has been shown to influence risk perceptions related to hazards. In this study we sought to examine whether order and amount of risk and benefit information influences patients’ perceived value of a proposed new medication.

Methods: We created 5 videos of a physician describing a new medication. The videos were identical except for the order and number of side effects (SEs) and benefits presented (see Table). Subjects with a systemic inflammatory rheumatic disease were randomly assigned to view one of the videos. Perceived medication value (PMV) was assessed by having subjects choose: the risks outweigh the benefits, the risks and benefits are equally balanced or the benefits outweigh the risks. We subsequently examined whether differences in the order and amount of information was associated with subjects’ PMV. This outcome was chosen because one’s overall impression more strongly predicts behavior than recall of verbatim information. We also examined the association of demographic characteristics (age, minority status, and difficulty paying for medications), attitudes towards illness and treatment (factor analysis of illness perceptions, patient activation and trust resulting in 4 factors: worry about illness, perceived treatment efficacy, impact of illness, patient activation), and current medications on PMV using bivariate analyses. Variables found to be significant (p<0.05) were included in a multinomial logistic regression model. Because of the known influence of numeracy on risk perception, all analyses were stratified by high versus low subjective numeracy (dichotomized at the median).

Results: 389 subjects participated: mean (SD) age= 55 (14), 75% female, 40% minority (African American and/or Hispanic). In bivariate analyses, the order and number of SEs and benefits, current use of prednisone, and minority status were associated with PMV in subjects with high numeracy (n=242). Presenting SEs first or between benefits were both associated with more negative PMV compared to the reference video (3 benefits followed by 6 SEs) (See Table). Among subjects with low numeracy (n=142), the order and number of risk and benefits presented were not associated with PMV. In bivariate analyses, use of a biologic, difficulty paying for medications, perceived treatment efficacy, patient activation, and minority status, were associated with PMV in subjects with low numeracy. Except for current use of a biologic, all remained significant in the multivariate model (see Table).

Conclusion: Order and amount of information matter, but only in patients with high subjective numeracy. Minority patients have a much more negative PMV compared to Caucasian, non-Hispanic patients, regardless of their level of numeracy.

Table: Multinomial logistic regression model examining association of risk-benefit presentation and patients characteristics on perceived medication value.

Variable

Perceived   Medication Value (Ref= Risks outweigh Benefits)

Adjusted   Odd Ratio (95% CI)

High   Numeracy

 

 

Video (Ref= 3 benefits   → 6 SEs)

 

 

6 benefits → 6 SEs

Balanced

1.87   (0.59 – 5.98)

 

Benefits outweigh   Risks

0.45   (0.14 – 1.48)

6 benefits → 3 SEs

Balanced

0.79   (0.24 –  2.64)

 

Benefits outweigh   Risks

0.60   (0.19 – 1.83)

6 SEs → 3 benefits

Balanced

0.47   (0.16 – 1.40)

 

Benefits outweigh   Risks

0.20 (0.07 – 0.58)

3 benefits → 6 SEs → 3   benefits

Balanced

0.54   (0.18 – 1.66)

 

Benefits outweigh   Risks

0.26   (0.09 – 0.78)

Currently on   prednisone

Balanced

0.75 (0.34 – 1.67)

 

Benefits outweigh   Risks

1.77 (0.82 – 3.80)

Minority vs Caucasian

Balanced

0.95   (0.48 – 1.89)

 

Benefits outweigh   Risks

0.25 (0.11 – 0.58)

 

 

 

Low   Numeracy

 

 

Perceived treatment   efficacy

Balanced

1.46   (0.90 – 2.37)

 

Benefits outweigh   Risks

2.22 (1.28 – 3.83)

Patient activation

Balanced

1.75 (1.09 – 2.81)

 

Benefits outweigh   Risks

1.05   (0.62 – 1.78)

Currently on a   biologic

Balanced

1.13   (0.35 – 3.66)

 

Benefits outweigh   Risks

2.64   (0.87 – 8.04)

Difficulty paying for   medications

Balanced

0.17 (0.07 – 0.44)

 

Benefits outweigh   Risks

0.73   (0.27 – 2.00)

Minority vs Caucasian

Balanced

0.23 (0.09 – 0.62)

 

Benefits outweigh   Risks

0.22 (0.08 – 0.63)


Disclosure:

L. Fraenkel,
None;

R. Street,
None;

H. Chowdhary,
None;

S. Swift,
None;

E. Peters,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-the-order-or-amount-of-risk-benefit-information-presented-influence-patients-perceived-value-of-a-proposed-new-medication/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology